Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1/2 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Skin Neoplasms 1Melanoma 1Leukoplakia 1Leukokeratosis, Hereditary Mucosal 1Carcinoma, Basal Cell 1

Interventions

pembrolizumab 157Nivolumab 132Ipilimumab 77Cyclophosphamide 46Specimen Handling 44Magnetic Resonance Spectroscopy 39cemiplimab 35Biopsy 31fludarabine 28trametinib 24relatlimab 24binimetinib 23Interleukin-2 21fludarabine phosphate 20dabrafenib 20atezolizumab 20Radiotherapy 20Opdualag 19Radiosurgery 18CTLA-4 Antigen 18encorafenib 17aldesleukin 17Blood Specimen Collection 17avelumab 14Immunoglobulin G 14Disulfides 13lenvatinib 11Bevacizumab 11lifileucel 10Paclitaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Imiquimod × Dermatologic × 1 year × Clear all
NCT03276832 2026-03-19

Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma

Mayo Clinic

Phase EARLY_PHASE1 Completed
7 enrolled 11 charts
Dermatologic

Melanoma

NCT07210775 2026-03-04

Topical Imiquimod Treatment of Oral Dysplasia

University of Southern California

Phase 1/2 Recruiting
20 enrolled
DermatologicHead & Neck

Leukoplakia, Leukokeratosis, Hereditary Mucosal

NCT03534947 2025-12-16

SONIB

Melanoma Institute Australia

Phase 2 Completed
16 enrolled
Dermatologic

Carcinoma, Basal Cell, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡